Form 4: TOI CFO Carter Reports RSU Award, Tax-Related Stock Sale

The Oncology Institute's CFO, Robert Ross Carter, reported the acquisition of 202,914 shares through an RSU award and the sale of 20,320 shares to cover tax liabilities.

Summary

• Robert Ross Carter, Chief Financial Officer of The Oncology Institute, Inc. (TOI), reported changes in his beneficial ownership of common stock.
• On March 27, 2026, Carter acquired 202,914 shares of common stock through a Restricted Stock Unit (RSU) award at a price of $0.
• Also on March 27, 2026, Carter disposed of 20,320 shares of common stock at a price of $3.07 per share.
• This disposition was executed to cover tax liabilities arising from the vesting of an RSU award on March 31, 2026.
• Following these transactions, Carter beneficially owns 416,405 shares of common stock directly.
• The RSU awards vest over four years, with 1/4 vesting on the first anniversary of the Vesting Commencement Date, and the remainder vesting in three equal annual installments, subject to continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The RSU award signifies continued executive compensation and retention, while the tax-related sale is a routine occurrence and not indicative of negative sentiment.

Positives

• The acquisition of 202,914 shares via an RSU award demonstrates continued compensation and retention of a key executive.
• The RSU vesting schedule aligns the CFO's long-term interests with shareholder value creation over a four-year period.

Negatives

• The sale of 20,320 shares, even for tax purposes, reduces the CFO's direct beneficial ownership by that amount.

Risks

• The RSU awards are subject to continued service with the company through the vesting dates, meaning unvested shares could be forfeited if employment ceases.
• The value of the RSU awards and the shares beneficially owned is subject to the market price fluctuations of The Oncology Institute's common stock.

Future Outlook

The RSU awards have a vesting schedule that extends over four years, with portions vesting annually, indicating a long-term incentive structure for the Chief Financial Officer.

Industry Context

StockSavvy.ai notes that RSU awards and subsequent tax-related sales are standard practices for executive compensation in publicly traded companies across various industries, including healthcare services like oncology. This type of transaction is a common mechanism for aligning executive incentives with long-term company performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a common practice, comparable to compensation structures seen in healthcare peers such as DaVita Inc. or Tenet Healthcare Corporation, which also utilize equity awards to incentivize and retain key management.
• The four-year vesting schedule is typical for long-term incentive plans, similar to those observed in many S&P 500 companies, ensuring executive commitment over a sustained period.
• The sale of shares to cover tax liabilities upon RSU vesting is a standard and expected event, not indicative of a lack of confidence, and is a common occurrence among executives receiving equity compensation across all sectors.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and ownership, showing alignment of interests through long-term equity awards. The tax-related sale is a common event and generally not a cause for concern.
• Employees: Reflects the company's compensation practices for its leadership.

Next Steps

• Future vesting of the remaining RSU awards according to the four-year schedule, subject to continued service.

Key Dates

Recommendation

This Form 4 details a routine executive compensation event involving an RSU award and a subsequent tax-related sale. Such transactions are common and do not typically provide a strong signal for a change in investment recommendation. The long-term vesting schedule for the RSU award suggests continued alignment of the CFO's interests with the company's performance, supporting a 'hold' stance for existing investors.

Keywords

The Oncology Institute, TOI, Robert Ross Carter, CFO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Award, Beneficial Ownership, Equity Compensation, Tax Liabilities